Rockefeller Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Rockefeller Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.8M	Buy	433,376 +61,179	+16%	+$3.35M	0.04%	419
2026 Q1	$21M	Buy	372,197 +10,626	+3%	+$620K	0.04%	431
2025 Q4	$21.5M	Buy	361,571 +5,043	+1%	+$275K	0.04%	424
2025 Q3	$19.3M	Buy	356,528 +33,045	+10%	+$1.89M	0.04%	430
2025 Q2	$17.8M	Buy	323,483 +18,081	+6%	+$1.06M	0.04%	423
2025 Q1	$21.6M	Buy	305,402 +2,902	+1%	+$195K	0.05%	341
2024 Q4	$19.9M	Buy	302,500 +35,867	+13%	+$2.4M	0.05%	343
2024 Q3	$18.7M	Buy	266,633 +37,805	+17%	+$3.16M	0.05%	358
2024 Q2	$18.8M	Buy	228,828 +20,172	+10%	+$1.68M	0.05%	336
2024 Q1	$18.2M	Buy	208,656 +18,200	+10%	+$1.63M	0.05%	354
2023 Q4	$18.4M	Buy	190,456 +10,760	+6%	+$952K	0.06%	305
2023 Q3	$15.9M	Sell	179,696 -372,811	-67%	-$33.2M	0.06%	317
2023 Q2	$47.9M	Sell	552,507 -176,939	-24%	-$16.7M	0.19%	137
2023 Q1	$70.9M	Buy	729,446 +202,410	+38%	+$21M	0.31%	78
2022 Q4	$54.5M	Sell	527,036 -492,384	-48%	-$46.2M	0.27%	87
2022 Q3	$86.4M	Sell	1,019,420 -98,181	-9%	-$8.74M	0.45%	48
2022 Q2	$92.6M	Sell	1,117,601 -14,734	-1%	-$1.17M	0.49%	41
2022 Q1	$87.3M	Sell	1,132,335 -7,502	-0.7%	-$628K	0.42%	53
2021 Q4	$101M	Sell	1,139,837 -12,022	-1%	-$992K	0.47%	40
2021 Q3	$89M	Buy	1,151,859 +338,406	+42%	+$26.7M	0.47%	40
2021 Q2	$67.9M	Buy	813,453 +53,161	+7%	+$4.21M	0.38%	52
2021 Q1	$57.4M	Sell	760,292 -120,044	-14%	-$9.81M	0.39%	53
2020 Q4	$77.2M	Buy	880,336 +4,800	+0.5%	+$381K	0.58%	33
2020 Q3	$66.6M	Buy	875,536 +335,439	+62%	+$33.9M	0.62%	26
2020 Q2	$66.6M	Buy	540,097 +532,179	+6,721%	+$52.9M	0.7%	25
2020 Q1	$669K	Buy	7,918 +3,956	+100%	+$341K	0.01%	548
2019 Q4	$335K	Buy	3,962 +74	+2%	+$5.59K	﹤0.01%	649
2019 Q3	$262K	Buy	3,888 +3,132	+414%	+$241K	﹤0.01%	573
2019 Q2	$65K	Sell	756 -621	-45%	-$53.1K	﹤0.01%	773
2019 Q1	$122K	Buy	+1,377	New	+$128K	﹤0.01%	709

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Rockefeller Capital Management's BMRN Position: Q2 2026 in Review

Rockefeller Capital Management increased its BioMarin Pharmaceuticals (BMRN) stake by 16% in Q2 2026, buying an estimated $3.35M and bringing the position to 433,376 shares worth $24.8M. The position accounts for 0.04% of the portfolio, ranked #419.

Rockefeller Capital Management first reported a position in BMRN in Q1 2019 and has held it in 30 quarters since. The position peaked at $101M in Q4 2021. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Rockefeller Capital Management held 433,376 shares of BioMarin Pharmaceuticals worth $24.8M as of Q2 2026.
Rockefeller Capital Management bought 61,179 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $3.35M.
BioMarin Pharmaceuticals made up 0.04% of Rockefeller Capital Management's portfolio in Q2 2026, its #419 holding.
Rockefeller Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
Rockefeller Capital Management's BioMarin Pharmaceuticals position peaked at $101M in Q4 2021.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.